Radiation sensitizing agents in clinical radiation and chemotherapy.

Patients with bronchogenic carcinoma or with advanced pediatric solid tumours were treated with various radiation therapy schedules alone or with a new alkylating carbamate: AB 132. Drug therapy appeared to potentiate radiation therapy results without significant toxicity except for certain neurologic symptoms (myasthenia, nightmares, disturbances of taste and smell). The latter appeared to be related to acetylcholinesterase and pseudocholinesterase inhibition.